- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01919385
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia
Feasibility Study Assessing the Ability of an Insulin Pump-controlling Algorithm to Minimize Hypoglycemia in Patients With Type 1 Diabetes in a Clinical Research Setting
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Forventet)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Santa Barbara, California, Forenede Stater, 93105
- Samsum Diabetes Reserach Inst.
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Age 21-65 years
- Type 1 diabetes mellitus for at least one year
- Currently using an insulin infusion pump for at least the past 6 months
Exclusion Criteria:
- Pregnancy
- History of Diabetic Ketoacidosis (DKA) in the past six months
- History of severe hypoglycemia (Seizure, unconsciousness) in the past 6 months
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Grundvidenskab
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: type 1 diabetes
Predictive Low Glucose Minimizer (PLGM) System
|
This study is a non-randomized feasibility study enrolling type 1 diabetics who are currently using an insulin pump.
Participating Investigators will closely monitor the study subject in a clinical research center environment for approximately 30 hours, while controller algorithm determined insulin doses are delivered by an insulin pump, and utilizing continuous glucose monitoring results.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Evaluate the performance of the System while the subject is under close medical supervision in the Clinical Research Center (CRC) setting
Tidsramme: 1 week after subject is enrolled in the study
|
Evaluating the ability of the system to predict a fall or rise in glucose values below or above a low glucose threshold, and take the corresponding appropriate action of reducing or suspending insulin delivery in order to keep the subject's glucose above this threshold, or resuming insulin delivery at the current basal rate upon the increase of glucose above this threshold. Ability of the system to issue timely and accurate warnings. |
1 week after subject is enrolled in the study
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Capturing the number of Adverse Events as a measure of assessing subject safety
Tidsramme: 1 week after subject is enrolled in the study
|
Understand the System's ability to safely keep the subject glucose levels within designated threshold.
The subject and the device will be continuously monitored by the Principle Investigator and Algorithm Engineer to ensure proper function of the device and subject safety.
All Adverse Events will be captured on the CRF.
|
1 week after subject is enrolled in the study
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Howard Zisser, MD, Samsum Diabetes Reserach Inst.
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Skøn)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- 3108873,
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Type 1 diabetes
-
COUR Pharmaceutical Development Company, Inc.RekrutteringType 1 diabetes | Type 1 diabetes mellitus | T1DM | T1D | Type 1-diabetes i ungdomsårene | Type 1-diabetes hos børn | Type 1-diabetespatienter | Type 1 diabetes melitis | T1DM - Type 1 Diabetes Mellitus | Type 1-diabetes (juvenil debut)Forenede Stater
-
Lund UniversityTilmelding efter invitationType 1 diabetes mellitus | Fase 2 Type 1-diabetes | Fase 1 type 1 diabetes | Trin 3 type 1 diabetesSverige
-
Oxford Brookes UniversityUniversity of OxfordAfsluttetFysisk aktivitet | Mental sundhed velvære 1 | Kognitiv funktion 1, Social | Akademisk opnåelse | KonditionstestDet Forenede Kongerige
-
Superior UniversityAktiv, ikke rekrutterendeType 2 Diabetes Mellitus 1Pakistan
-
Thomas Aagaard RasmussenAarhus University Hospital; The Alfred; Germans Trias i Pujol Hospital; Walter...Rekruttering
-
SanionaAfsluttet
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionAfsluttet
-
Calliditas Therapeutics ABAfsluttet
-
Immunocore LtdIkke rekrutterer endnuType 1 diabetes | Diabetes type 1 | Type 1-diabetes (T1D)
-
Penn State UniversityPenn State HealthIkke rekrutterer endnu